Shijia Zhang is an Oncology physician. OpenAlex indexes 29 publications with 303 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
403 S Kings Ave Ste 100
Brandon, FL 335115962
Telephone
813-982-3460Provider last certified this registry record 4 Feb 2025.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20254 payments
- GlaxoSmithKline, LLC.Program year20253 payments
- Celgene CorporationProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
47.5%Iron, parenteral preparations39.3%Ferric carboxymaltose100%Part B, office-administered≥29 patientsErythropoiesis-stimulating Agent8.2%Darbepoetin alfa80%Epoetin alfa20%Part B, office-administered≥16 patients+ 1 more class in this area
Cancer & immunology
35.9%PD-1 inhibitor29%Nivolumab51%Pembrolizumab49%Part B, office-administered≥23 patientsCD38-directed Cytolytic Antibody5.8%Daratumumab100%Part B, office-administered≥12 patients+ 9 more classes in this area
Metabolism & gastrointestinal
10%Substance P/Neurokinin-1 Receptor Antagonist7.3%Aprepitant100%Part B, office-administered≥21 patientsSerotonin-3 Receptor Antagonist1.8%Palonosetron hcl70%Ondansetron hydrochloride26%Ondansetron Hcl4%Part D + Part B≥53 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade
Cancer Immunology Immunotherapy
2022 - Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer
Clinical Medicine Insights Oncology
2021 - Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
Blood Cancer Journal
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”